Mark Shrime graduated summa cum laude from Princeton University in 1996 with a BA in molecular biology. His graduating thesis involved computer modeling of the protein-DNA interaction for Nm23, a tumor suppressor implicated in breast, lung, and head and neck cancer. He received his MD from the University of Texas in 2001, after taking a year to teach organic chemistry in Singapore. Medical school was followed by a residency in otolaryngology at the joint Columbia/Cornell program in Manhattan, which he completed in 2006 and during which he received the Arnold P. Gold Humanism in Teaching award; this, in turn, was followed by a fellowship in head and neck surgical oncology at the University of Toronto in 2007. He completed a second fellowship in microvascular reconstructive surgery, also at the University of Toronto, in 2008. During his residency and fellowships, he published two cost-effectiveness studies on questions in otolaryngology and in thyroid cancer, and was the first to identify a novel independent prognostic indicator in head and neck cancer.
Between his two fellowships, he worked with Mercy Ships as a surgeon in Liberia and has returned to West Africa every year to continue his clinical and educational work in surgery. In May, 2011, he graduated with an MPH in global health from the Harvard School of Public Health, where he was a finalist for both the Albert Schweitzer award and the HSPH Student Recognition award. He was previously an assistant professor in otolaryngology at Boston University and in practice as a head and neck surgical oncologist at Boston Medical Center. Since 2011, he has been a clinical instructor in otology and laryngology at the Harvard Medical School, and a otolaryngologist at the Massachusetts Eye and Ear Infirmary. In addition, he is pursuing a PhD in health policy at the Harvard Interfaculty Initiative in Health Policy, where he is interested in the study of cost-effective delivery platforms for surgical care in the developing world. He has a secondary interest in decision-making at the end of life.